Symvivo

News

Symvivo Receives Funding for COVID-19 Vaccine Program

Contribution of up to $2.8 million will support clinical advancement of bacTRL-Spike™ oral vaccine candidate.

October 20, 2020

First-in-Human Trial of Symvivo’s Oral COVID-19 Vaccine Candidate, bacTRL-Spike™

Symvivo Corporation has received regulatory approval to initiate a Phase 1, first-in-human trial of bacTRL-Spike™, an oral DNA vaccine candidate for the prevention of COVID-19.

October 19, 2020

Appointment of Lloyd Mackenzie as President and Chief Operating Officer

Announcing the appointment of Lloyd Mackenzie as the company’s President and Chief Operating Officer.

September 16, 2020

TOPICS